The US Food and Drug Administration’s February 28 approval of Xermelo (telotristat) marks the first drug successfully commercialized by Lexicon Pharmaceuticals. Founded in 1995 to pursue new target discovery, Lexicon, based in The Woodlands, Texas, built an extensive library of novel targets using a functional genomics approach and mouse knockout technology…

Para acessar a publicação na íntegra clique  aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 399